Meta-Analysis
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 14, 2016; 22(22): 5285-5292
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5285
Table 1 Overall characteristics of studies included in meta-analysis
Ref.YearPatients characteristicsStudy designOutcome (SVR %)
Alqahtani et al[31]2015HCV mono-infected patientsa) SOF + RBV + PEG-IFN (n = 18)a) 89%
TARGET cohortb) SOF + RBV (n = 133)b) 65%
Randomized by cirrhosis and previous treatment
50% Treatment naïve
51% Cirrhosis
Chulanov et al[32]2014HCV mono-infected patientsa) SOF + RBV 16 wk (n = 30)a) 87%
Russian multicenter cohortb) SOF + RBV 24 wk (n = 31)b) 90%
Randomized by cirrhosis
100% Treatment naïve
18% Cirrhosis
Dalgard et al[33]2015HCV mono-infected patientsa) SOF + RBV + PEG-IFN 12 wk (n = 25)a) 92%
Scandinavian cohort studyb) SOF + RBV 24 wk (n = 33)b) 79%
51% Treatment naïve
82% Cirrhosis
Foster et al[17](BOSON)2015HCV mono-infected patientsa) SOF + RBV + PEG-IFN 12 wk (n = 181)a) 93%
Randomized studyb) SOF + RBV 16 wk (n = 181)b) 71%
51% Treatment naïvec) SOF + RBV 24 wk (n = 182)c) 84%
31% Cirrhosis
Foster et al[27]2015HCV mono-infected patientsa) SOF + DCV 12 wk (n = 7)a) 71%
NHS England Early Access Programb) SOF + DCV + RBV 12 wk (n = 113)b) 81%
100% Decompensated Cirrhosisc) SOF + LDV 12 wk (n = 7)c) 57%
d) SOF + LDV + RBV 12 wk (n = 61)d) 72%
Gane et al[29] (ELECTRON-2)2015HCV mono-infected patientsa) SOF + LDV 12 wk (n = 25)a) 64%
Randomized studyb) SOF + LDV + RBV 12 wk (n = 26)b) 100%
50% Treatment naïvec) SOF + LDV + RBV 12 wk (n = 50)c) 82%
32% Cirrhosis
Hezode et al[34]2015HCV mono-infected patientsa) SOF + DCV 12 wk (n = 26)a) 85%
French Compassionate Use Programb) SOF + DCV + RBV 12 wk (n = 4)b) 100%
27% Treatment naïvec) SOF + DCV 24 wk (n = 35)c) 91%
94% Cirrhosisd) SOF + DCV + RBV 24 wk (n = 13)d) 92%
Ingiliz et al[35]2015HCV-HIV co-infected patientsa) SOF + RBV + PEG-IFN 12 wk (n = 31)a) 94%
German multicenter cohort studyb) SOF + RBV 24 wk (n = 23)b) 91%
50% Treatment naïve38% Cirrhosis
Sulkowski et al[22](PHOTON)2014HCV-HIV co-infected patientsa) SOF + RBV 12 wk (n = 42)a) 67%
International multicenter cohortb) SOF + RBV 24 wk (n = 123)b) 89%
25% Treatment naïve
Sulkowski et al[36]2014HCV mono-infected patientsa) SOF + DCV 24 wk (n = 13)a) 92%
Randomized studyb) SOF + DCV + RBV 24 wk (n = 5)b) 80%
100% Treatment naïve
14% Cirrhosis
Welzel et al[28]2015HCV mono-infected patientsa) SOF + DCV 24 wk (n = 11)a) 100%
European Compassionate Use Programb) SOF + DCV + RBV 24 wk (n = 13)b) 85%
72% Cirrhosis
Zeuzem et al[37] (VALENCE)2014HCV mono-infected patientsa) SOF + RBV 12 wk (n = 11)a) 27%
Randomized studyb) SOF + RBV 24 wk n = 250)b) 84%
41% Treatment naïve
24% Cirrhosis